# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

# C Proprietary and Established Names

CAPI 3 Immunotyping, Capillarys 3 Tera

# D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>CFF</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5510 -Immunoglobulins A, G,M, D, And EImmunological TestSystem</td><td rowspan=1 colspan=1>IM - Immunology</td></tr><tr><td rowspan=1 colspan=1>DFH</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5550 -Immunoglobulin (lightchain specific)immunological test system</td><td rowspan=1 colspan=1>IM - Immunology</td></tr><tr><td rowspan=1 colspan=1>DEH</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5550 -Immunoglobulin (lightchain specific)immunological test system</td><td rowspan=1 colspan=1>IM - Immunology</td></tr><tr><td rowspan=1 colspan=1>CEF</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.1630 - Protein(fractionation) test system</td><td rowspan=1 colspan=1>CH - Clinical Chemistry</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: Addition of a new matrix (urine) to a previously cleared device.   
B Measurand: Monoclonal Immunoglobulins (IgG, IgA, IgM, Kappa, Lambda)   
C Type of Test: Capillary Zone Electrophoresis

III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The CAPI 3 IMMUNOTYPING kit is designed for the qualitative detection and the characterization of monoclonal proteins (immunotyping) in human urine and serum with the CAPILLARYS 3 TERA instrument, SEBIA, for capillary electrophoresis. It is used in conjunction with the CAPI 3 PROTEIN(E) 6 kit, SEBIA, designed for proteins separation into 6 major fractions in alkaline buffer $\left( \mathsf { p H } 9 . 9 \right)$ . The CAPILLARYS 3 TERA instrument performs all procedural sequences automatically to obtain a protein profile for qualitative analysis. Each urine or serum sample is mixed with individual antisera that are specific against gamma $( \mathrm { I g } \mathrm { G } )$ , alpha $( \mathrm { I g } \mathrm { \bf A } )$ and mu $( \mathrm { I g } \mathrm { M } )$ heavy chains, and kappa (free and bound) light chains and lambda (free and bound) light chains, respectively. The proteins, separated in silica capillaries, are directly detected by their absorbance at $2 0 0 \mathrm { n m }$ . The electrophoregrams are evaluated visually to detect the presence of specific reactions with the suspect monoclonal proteins. For In Vitro Diagnostic Use.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

D Special Instrument Requirements:

CAPILLARYS 3 TERA instrument

# A Device Description:

The CAPI 3 IMMUNOTYPING kit includes the following components:

• Sample diluent   
• Pierceable cap for the Sample diluent vial   
• Rack with electrophoresis (ELP) solution and antiserum tubes   
• ELP solution   
• Mammalian immunoglobulins antihuman gamma heavy chains   
• Mammalian immunoglobulins antihuman alpha heavy chains   
• Mammalian immunoglobulins antihuman mu heavy chains   
• Mammalian immunoglobulins antihuman kappa (free and bound) light chains   
• Mammalian immunoglobulins antihuman lambda (free and bound) light chains

# B Principle of Operation:

The CAPILLARYS 3 TERA instrument uses the principle of capillary electrophoresis in a liquid medium. With this technique, charged molecules are separated by their electrophoretic mobility in an alkaline buffer with a specific pH. Protein separation is performed in a high voltage electrical field. The separated proteins are directly detected using absorbance at $2 0 0 \mathrm { n m }$ at the cathodic end of the capillary. Separation occurs according to the electrolyte $\mathsf { p H }$ and is driven by electroosmotic flow. The CAPILLARYS 3 TERA instrument has silica capillaries functioning in parallel allowing 12 simultaneous analyses.

With the CAPI 3 IMMUNOTYPING procedure, the immunotyping using specific antibodies is performed to identify abnormal fractions in serum or urine protein profiles through a process called Immunofixation by Subtraction (Immunotyping). Here, the addition of immunoglobulin class specific antisera to the patient sample causes a shift in the electrophoretic mobility of the specific peaks, allowing the identification of the class of the aberrant peak.

# C Instrument Description Information:

<table><tr><td rowspan=1 colspan=1>Modes of Operation</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Does the applicant&#x27;s device contain the ability to transmit data to a computer,webserver, or mobile device?</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1>□</td></tr><tr><td rowspan=1 colspan=1>Does the applicant&#x27;s device transmit data to a computer, webserver, or mobile deviceusing wireless transmission?</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>X</td></tr><tr><td rowspan=1 colspan=3>Software</td></tr><tr><td rowspan=1 colspan=1>FDA has reviewed applicant&#x27;s Hazard Analysis and software development processesfor this line of product types.</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1></td></tr></table>

A Predicate Device Name(s): Capillarys Immunotyping, Capillarys 2 Instrument, IT/IF Control, Capillarys 2 Flex Piercing Instrument CAPI 3 Immunotyping, Capillarys 3 Tera, IT/IF Control

B Predicate 510(k) Number(s): K130500 K161928

C Comparison with Predicate(s):   

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=4>K192095</td><td rowspan=1 colspan=1>K130500</td><td rowspan=1 colspan=1>K161928</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=4>IMMUNOTYPING,CAPILLARYS 3TERA, IT/IF Control</td><td rowspan=1 colspan=1>CAPILLARYSIMMUNOTYPING andIT/IF Control using theCAPILLARYS 2Instrument andCAPILLARYS 2 FLEX-PIERCING Instrument</td><td rowspan=1 colspan=1>CAPI 3IMMUNOTYPING,CAPILLARYS 3 TERA,IT/IF Control</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Similarities</td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=12 colspan=1>Intended Use/IndicationsFor Use</td><td rowspan=1 colspan=4>The CAPI 3IMMUNOTYPING kitis designed for thequalitative detectionand the characterizationof monoclonal proteins(immunotyping) inhuman urine and serum</td><td rowspan=1 colspan=1>The CAPILLARYSIMMUNOTYPING kitis designed for thedetection andcharacterization ofmonoclonal proteins(immunotyping) inhuman urine and serum</td><td rowspan=12 colspan=1>The CAPI 3IMMUNOTYPING kitis designed for thequalitative detection andcharacterization ofmonoclonal proteins(immunotyping) inhuman serum with theCAPILLARYS 3 TERAinstrument, SEBIA, forcapillary electrophoresis.It is used in conjunctionwith CAPI 3PROTEIN(E) 6 kit,SEBIA, designed forprotein separation into 6major fractions inalkaline buffer (pH 9.9).The CAPILLARYS 3TERA instrumentperforms all proceduralsequences automaticallyto obtain a protein</td></tr><tr><td rowspan=1 colspan=4>with the CAPILLARYS</td><td rowspan=1 colspan=1>with the CAPILLARYS,</td></tr><tr><td rowspan=2 colspan=4>3 TERA instrument,SEBIA, for capillaryelectrophoresis. It is</td><td rowspan=1 colspan=1>the CAPILLARYS 2</td></tr><tr><td rowspan=1 colspan=1>and the CAPILLARYS2 FLEX-PIERCING,</td></tr><tr><td rowspan=1 colspan=4>used in conjunction</td><td rowspan=1 colspan=1>SEBIA, for capillary</td></tr><tr><td rowspan=1 colspan=4>with the CAPI 3</td><td rowspan=2 colspan=1>electrophoresis. It isused in conjunction with</td></tr><tr><td rowspan=1 colspan=4>PROTEIN(E) 6 kit,</td></tr><tr><td rowspan=2 colspan=4>SEBIA, designed forproteins separation into</td><td rowspan=5 colspan=1>the SEBIACAPILLARYSPROTEIN(E) 6 kit,designed for proteinseparation into 6 majorfractions in alkalinebuffer (pH 10.0).The CAPILLARYS,</td></tr><tr><td rowspan=1 colspan=3>proteins separation into6 major fractions in</td></tr><tr><td rowspan=1 colspan=4>6 major fractions inalkaline buffer (pH 9.9).</td></tr><tr><td rowspan=2 colspan=4>The CAPILLARYS 3TERA instrumentperforms all proceduralsequences automatically</td></tr><tr><td rowspan=1 colspan=1></td></tr></table>

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">to obtain a proteinprofile for qualitativeanalysis. Each urine orserum sample is mixedwith individual antiserathat are specific againstgamma (Ig G), alpha (IgA) and mu (Ig M)heavy chains, and kappa(free and bound) lightchains and lambda (freeand bound) light chains,respectively.The proteins, separatedin silica capillaries, aredirectly detected bytheir absorbance at 200nm.The electropherogramsare evaluated visually todetect the presence ofspecific reactions withthe suspect monoclonalproteins.For In Vitro DiagnosticUse.</td><td colspan="1" rowspan="1">CAPILLARYS 2 andthe CAPILLARYS 2FLEX-PIERCINGperform all proceduralsequences automaticallyto obtain a proteinprofile for qualitativeanalysis. Each urine orserum sample is mixedwith individual antiserathat are specific againstgamma (Ig G), alpha (IgA) and mu (Ig M) heavychains, and kappa (freeand bound) light chainsand lambda (free andbound) light chains,respectively. Theproteins, separated insilica capillaries, aredirectly detected by theirabsorbance at 200 nm.The electropherogramsare evaluated visually todetect the presence ofspecific reactions withthe suspect monoclonalproteins.For In Vitro DiagnosticUse.</td><td colspan="1" rowspan="1">profile for qualitativeanalysis. Each serumsample is mixed withindividual antisera thatare specific againstgamma (Ig G), alpha (IgA) and mu (Ig M) heavychains, and kappa (freeand bound) light chainsand lambda (free andbound) light chains,respectively.The proteins, separatedin silica capillaries, aredirectly detected by theirabsorbance at 200 nm.The electrophoregramsare evaluated visually todetect the presence ofspecific reactions withthe suspect monoclonalproteins.For In Vitro DiagnosticUse.</td></tr><tr><td colspan="1" rowspan="1">Quality Control</td><td colspan="1" rowspan="1">The IT/IF Control</td><td colspan="1" rowspan="1">The IT/IF Control isdesigned to qualitycontrol the qualitativedetection andcharacterization ofhuman monoclonalimmunoglobulins (Ig G,Ig A, Ig M, Kappa andLambda) with theelectrophoresis methods:Immunotypingperformed usingcapillary electrophoresison SEBIACAPILLARYS 2 andCAPILLARYS 2 FLEX</td><td colspan="1" rowspan="1">The IT/IF Control isdesigned to qualitycontrol the qualitativedetection andcharacterization of humanmonoclonalimmunoglobulins (IgG,IgA, IgM, Kappa andLambda) with theelectrophoresis methods:- Immunotypingperformed using capillaryelectrophoresis on SEBIACAPILLARYS 2,CAPILLARYS 2 FLEX-PIERCING andCAPILLARYS 3 TERAinstruments and onSEBIA MINICAP</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">PIERCING instrumentsand on SEBIAMINICAP instrument,- Immunofixationmethods: SEBIAHYDRAGEL IF,HYDRAGEL IF Penta,HYDRAGEL BENCEJONES (Standard maskand Dynamic mask)performed using theHYDRASYS andHYDRASYS 2instruments and the K20electrophoresis chamber.The IT / IF Control isdesigned for laboratoryuse. It should be used(with its barcode labelfor MINICAPprocedure) like a humanserum sample. Theelectrophoretic patternobtained is specific foreach batch of IT/IFcontrol.For In Vitro DiagnosticUse.</td><td colspan="1" rowspan="1">instrument, -Immunofixation methods:SEBIA HYDRAGEL IF,HYDRAGEL IF Penta,HYDRAGEL BENCEJONES (Standard maskand Dynamic mask)performed using theHYDRASYS andHYDRASYS 2instruments and the K20electrophoresis chamber.The IT/IF Control isdesigned for laboratoryuse. It should be used(with its barcode label forCAPILLARYS andMINICAP procedure)like a human serumsample. Theelectrophoretic patternobtained is specific foreach batch of IT/IFcontrol.For In Vitro DiagnosticUse.</td></tr><tr><td colspan="1" rowspan="1">Separation system</td><td colspan="1" rowspan="1">Free solution capillaryelectrophoresis(FSCE): proteinseparation in an alkalinebuffer (pH 9.9)according to theircharge, to theelectrolyte pH andelectroosmotic flow.Provides fast separationand good resolution.Electrophoregramsshow separatedfractions according totheir charge.</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum and Urine</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">Results</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent</td><td colspan="1" rowspan="1">Mammalian</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">immunoglobulins anti-human gamma heavychains, mammalianimmunoglobulinsantihuman alpha heavychains, mammalianimmunoglobulinsantihuman mu heavychains, mammalianimmunoglobulins anti-human kappa (free andbound) light chains,mammalianimmunoglobulinsantihuman lambda (freeand bound) light chains</td><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">b</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum and Urine</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">Results</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent</td><td colspan="1" rowspan="1">Mammalianimmunoglobulins anti-human gamma heavychains, mammalianimmunoglobulinsantihuman alpha heavychains, mammalianimmunoglobulinsantihuman mu heavychains, mammalianimmunoglobulins anti-human kappa (free andbound) light chains,mammalianimmunoglobulinsantihuman lambda (freeand bound) light chains</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Temperature Control</td><td colspan="1" rowspan="1">Peltier device</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Software for data processing</td><td colspan="1" rowspan="1">SEBIA PHORESISsoftware</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Reagent format</td><td colspan="1" rowspan="1">CAPI 3 ImmunotypingKit: Sample diluentRack with ELP solutiontube and antiserum tube</td><td colspan="1" rowspan="1">CAPILLARYSIMMUNOTYPING Kit:Antisera segmentcontaining ELP solution</td><td colspan="1" rowspan="1">One vial (lyophilized; 1.0mL)</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">SEBIA CAPILLARYS</td><td colspan="1" rowspan="1">SEBIA CAPILLARYS 2</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3 TERA</td><td colspan="1" rowspan="1">FLEX-PIERCINGSEBIA CAPILLARYS 2</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Analysis throughput</td><td colspan="1" rowspan="1">21 analyses / 2 hours</td><td colspan="1" rowspan="1">16 analyses / 2 hours</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Interface</td><td colspan="1" rowspan="1">PC interface + touchscreen</td><td colspan="1" rowspan="1">PC interface</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Detection system</td><td colspan="1" rowspan="1">Deuterium lamp andLED</td><td colspan="1" rowspan="1">Deuterium lamp</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Firmware</td><td colspan="1" rowspan="1">Included into theinstrument</td><td colspan="1" rowspan="1">Included into thePHORESIS software</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Number of separation units</td><td colspan="1" rowspan="1">12 parallel capillaries</td><td colspan="1" rowspan="1">8 parallel capillaries</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample tubes</td><td colspan="1" rowspan="1">uncapped tubes orcapped tubes dependingon the procedure</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sampleidentification</td><td colspan="1" rowspan="1">Bar code reading onsample tubes and RFIDlabels on sample racks</td><td colspan="1" rowspan="1">Bar code reading onboth sample racks andtubes</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent identification</td><td colspan="1" rowspan="1">Yes (RFID labels onreagent vials)</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Introduction of the samplesinto the automatic system</td><td colspan="1" rowspan="1">Primary maximalcapacity of 120 tubes(i.e. 15 sample racks),uninterruptedthroughput on sampleracks (8 positionsavailable).</td><td colspan="1" rowspan="1">Primary capacity of 13tubes for IT technique(i.e. 13 sample racks),uninterrupted throughputon sample racks. Onlyposition 1 on the samplerack contains sampletube.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent bay: maincompartment</td><td colspan="1" rowspan="1">Up to four analysisbuffers or hemolysingsolutions (identified byRFID labels); one wastecontainer, one containerfor the wash solution</td><td colspan="1" rowspan="1">CAPILLARYS 2 :Contains one vial ofwater, wash solution andbuffer container.CAPILLARYS 2 FLEX-PIERCING : Containsone vial of water, washsolution, hemolyzingsolution (for Hb and HbAlc techniques) andbuffer container.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent bay: secondarycompartment</td><td colspan="1" rowspan="1">Up to 3 vials and 1 rackwith immunotypingreagents (all RFIDtagged) in temperature-controlled environment(&lt; 15 °C); one RFIDlabeled vial and threetubes (for maintenance</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Same</td></tr><tr><td></td><td>solutions) at room temperature</td><td></td><td></td></tr></table>

# VI Standards/Guidance Documents Referenced:

Not applicable

VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

All results met the manufacturer’s pre-specified acceptance criteria.

# Repeatability

Four different urine samples with monoclonal proteins including Bence Jones proteins were run using the CAPI 3 IMMUNOTYPING URINE procedure on all capillaries of the same CAPILLARYS 3 TERA instrument using one lot of CAPI 3 IMMUNOTYPING kit. The four samples included IgG-kappa, Lambda Free, IgM-kappa $^ +$ kappa free, and IgA-Lambda $^ +$ lambda free. Each sample was analyzed with each reagent in duplicate (ELP solution, AntiIg G, Anti-Ig A, Anti-Ig M, Anti-Kappa and Anti-Lambda using the 12 capillaries. In this study all dilution programs were tested. For each tested reagent, all samples gave concordant results within run and between capillaries.

# Between-Instrument and Between-Lot Precision

Three different urine samples with monoclonal proteins including Bence Jones proteins were run using the CAPI 3 IMMUNOTYPING URINE procedure on three CAPILLARYS 3 TERA instruments and with three lots of CAPI 3 IMMUNOTYPING kit. The samples included one sample with two kappa free light chains, one sample with IgG-kappa immunoglobulin and one sample with Lambda free light chain. Each sample was analyzed on 18 runs over five working days (2 runs/day x 3 lots $_ { \textrm { X 3 } }$ instruments $= 1 8$ ). In this study, all dilution programs were tested. All samples gave concordant results for all runs on the three CAPILLARYS 3 TERA instruments and with the three lots of CAPI 3 IMMUNOTYPING kit.

2. Linearity:

Not applicable, this is a qualitative test.

3. Analytical Specificity/Interference:

This clearance is for the addition of urine to the acceptable matrices for a previously cleared device, where specificity/interference was demonstrated in the original clearance (see K130500).

# 4. Assay Reportable Range:

Not applicable, this is a qualitative test.

No reference standards and methods available. Controls are internally manufactured by the manufacturer from myeloma serum samples with representative Immunoglobulin G with kappa light chain (IgGK), Immunoglobulin A with kappa light chain (IgAK), and Immunoglobulin M with lambda light chain (IgML) monoclonal proteins and are validated by both Immunofixation Gel Electrophoresis and Capillary Electrophoresis methods.

Stability: The manufacturer provided data to support real-time stability of two years and onboard stability of two months for the CAPI 3 IMMUNOTYPING Kit.

# Sample Stability at $2 { - } 8 ^ { \circ } \mathrm { C }$

Ten urine samples. including normal and pathological urine samples, were analyzed at the beginning of the study (reference) and after one week storage at $2 { = } 8 ^ { \circ } \mathrm { C }$ (test), with the CAPI 3 IMMUNOTYPING URINE procedure performed with the CAPILLARYS 3 TERA instrument. The results obtained comply with the acceptance criteria defined by SEBIA for the CAPI 3 IMMUNOTYPING URINE procedure performed with the CAPILLARYS 3 TERA instrument. Urine samples can be stored for one week between 2 and $8 ^ { \circ } \mathrm { C }$ .

# Stability $= 7 0 / - 8 0 ^ { \circ } \mathrm { C }$

Eleven urine samples including normal and pathological urine samples were analyzed at the beginning of the study (reference) and after one month storage at $= 7 0 /$ $\underline { { - 8 0 ^ { \circ } \mathrm { C } } }$ (test), with the CAPI 3 IMMUNOTYPING URINE procedure performed with the CAPILLARYS 3 TERA instrument. The results obtained comply with the acceptance criteria defined by SEBIA for the CAPI 3 IMMUNOTYPING URINE procedure performed with the CAPILLARYS 3 TERA instrument. Urine samples can be stored for one month between $= 7 0$ and $\underline { { - 8 0 ^ { \circ } \mathrm { C } } }$ .

# 6. Detection Limit:

Serial dilutions were prepared in normal urine with three pathological urine samples exhibiting monoclonal components and analyzed using the CAPI 3 IMMUNOTYPING URINE procedure. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Type</td><td rowspan=1 colspan=1>Detection Limitmg/dL</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Lambda Free</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Kappa Free</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=2 colspan=1>3</td><td rowspan=1 colspan=1>IgG (Lambda)</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>Lambda</td><td rowspan=1 colspan=1>0.4</td></tr></table>

7. Assay Cut-Off:

Not applicable.

# B Comparison Studies:

# 1. Method Comparison with Predicate Device:

The method comparison study included 52 urines samples composed of 8 urine samples without monoclonal component and 44 urine samples with monoclonal component including Bence Jones proteins. The samples were tested using the CAPI 3 IMMUNOTYPING URINE procedure performed with the CAPILLARYS 3 TERA instrument (test technique) and the CAPILLARYS IMMUNOTYPING URINE procedure performed with the CAPILLARYS 2 instrument (reference technique). All electropherograms were evaluated visually for the qualitative results. This study demonstrated a $100 \%$ agreement between the two techniques.

<table><tr><td rowspan=1 colspan=1>Qualitative Results</td><td rowspan=1 colspan=1>Number of urine samples</td><td rowspan=1 colspan=1>Percent Agreement</td></tr><tr><td rowspan=1 colspan=1>IgG Lambda</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>IgG Kappa</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>IgG Lambda with Lambda free</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>IgG Kappa with Kappa free</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Lambda free</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Kappa free</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>IgM Kappa with Kappa free</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>IgA Lambda</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>IgA Lambda with Lambda free</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Without Monoclonal</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Grand Total</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>100%</td></tr></table>

2. Matrix Comparison:

Not applicable, the results in urine are not directly comparable to serum.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable, clinical studies were not required for the addition of this matrix.

2. Clinical Specificity: Not applicable, clinical studies were not required for the addition of this matrix.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

# D Clinical Cut-Off:

Not applicable, this is a qualitative test.

# E Expected Values/Reference Range:

Absence of monoclonal immunoglobulins in apparently healthy individuals

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.